The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Development of patient-accessible therapeutics for HCC
Mara Persano, MD, University Hospital of Cagliari, Cagliari, Italy, highlights how in patients with hepatocellular carcinoma (HCC) in Italy, sorafenib is the only available second-line treatment in the clinic with cabozantinib used as a third-line therapy. To improve patient outcomes, future clinical trials should prioritize the inclusion of drugs not yet reimbursed by pharmaceutical regulations, thereby broadening their availability and benefiting a larger patient population. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
